Piper Sandler Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Raises Target Price to $16
Fulcrum Therapeutics (FULC) Receives a Buy From Piper Sandler
Census Acquires Fulcrum to Enhance Data Collaboration and Modeling
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter
Is Fulcrum Therapeutics (NASDAQ:FULC) In A Good Position To Deliver On Growth Plans?
Fulcrum Therapeutics (NASDAQ:FULC) Delivers Shareholders Stellar 110% Return Over 1 Year, Surging 27% in the Last Week Alone
Fulcrum Therapeutics Price Target Maintained With a $23.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight on Fulcrum Therapeutics, Maintains $23 Price Target
Jack and Jill of America, Inc. Hosts "Your Health, Your Legacy" Health Fair and Blood Drive During the 46th National Convention in Minneapolis
Express News | Fulcrum Therapeutics Inc - Increased Size of Board From Eight to Nine Members
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
10 Health Care Stocks With Whale Alerts In Today's Session
Fulcrum Therapeutics to Participate in the Goldman Sachs' 45th Annual Global Healthcare Conference
Goldman Sachs Predicts up to 108% Rally for These 2 'Strong Buy' Stocks
Fulcrum Therapeutics (NASDAQ:FULC) Readies Phase 3 Candidate With Blockbuster Potential
Fulcrum Therapeutics Initiated at Overweight by Cantor Fitzgerald
Express News | Cantor Fitzgerald Initiates Coverage On Fulcrum Therapeutics With Overweight Rating, Announces Price Target of $23
Buy Rating Reaffirmed for Fulcrum Therapeutics Amid Sanofi Partnership and Promising Drug Prospects
Express News | Fulcrum Therapeutics Inc. : Oppenheimer Cuts Target Price to $14 From $16
Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target Is $15